New Strategies for Combined Radioiodine Therapy in Refractory Thyroid Cancer

2015 ◽  
Vol 8 (1) ◽  
pp. 26 ◽  
Author(s):  
So Won Oh ◽  
Jin Chul Paeng ◽  
June-Key Chung
Keyword(s):  
Thyroid Cancer ◽  
Radioiodine Therapy ◽  
New Strategies

Predictive factors determining incomplete response to radioiodine therapy in patients with differentiated thyroid cancer

2020 ◽  
Vol 64 (1) ◽  
Author(s):  
Ewelina Szczepanek-Parulska ◽  
Magdalena Wojewoda-Korbelak ◽  
Martyna Borowczyk ◽  
Malgorzata Kaluzna ◽  
Barbara Brominska ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Predictive Factors ◽  
Differentiated Thyroid Cancer ◽  
Radioiodine Therapy ◽  
Incomplete Response

scholarly journals Radioiodine therapy reduces the frequency of circulating tumour cells in patients with differentiated thyroid cancer

2021 ◽  
Author(s):  
Mathias Schmidt ◽  
Christina Antke ◽  
Katalin Mattes‐György ◽  
Hubertus Hautzel ◽  
Stephanie Allelein ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Radioiodine Therapy ◽  
Tumour Cells ◽  
Circulating Tumour Cells

Nuclear medical inpatient treatment in Germany

2010 ◽  
Vol 49 (02) ◽  
pp. 49-57 ◽  
Author(s):  
M. Dietlein ◽  
C. Reiners ◽  
R. Lorenz
Keyword(s):  
Nuclear Medicine ◽  
Thyroid Cancer ◽  
Inpatient Treatment ◽  
Radioiodine Therapy ◽  
Main Diagnosis ◽  
Medical Inpatient ◽  
Iodine Prophylaxis ◽  
Iodine Supply ◽  
Quality Report ◽  
Quality Reports

SummaryAll public licensed hospitals of Germany are obligated since 2004 to establish and to publish a structured biennial quality report. The aim of this study was to analyse the quality reports from 2008 of clinics with nuclear-medicine therapy ward and to investigate developments for the inpatient nuclear-medicine therapy by comparing the results with the quality reports of the years 2004 and 2006. Methods: All available structured quality reports of clinics with a nuclear-medicine therapy ward of the years 2004, 2006 and 2008 were evaluated. Results: The total number of inpatient treatment cases in 2008 amounted to 54 190 (2006: 54 884; 2004: 57 366). This corresponds to a decrease of 5.5% in comparison to 2004. The number of the therapy wards decreased at the same time to currently 117 (2006: 120; 2004: 124). Remarkable changes were found in the spectrum of the main diagnosis. Thus, the most frequent diagnosis with the ICD-code E05 (hyperthyroidism) decreased continuously from 37 747 treatments in 2004 and 34 764 in 2006 to 31 756 in the year 2008. In contrast, the ICD-diagnoses for thyroid cancer (C73, Z08) with 14 761 cases in 2008 increased with time (2006: 13 426; 2004: 12 581). Conclusions: In analogy to the observations from Europe after introduction of an iodine prophylaxis the improved iodine supply in Germany has led to a decline of the radioiodine therapy due to hyperthyroidism.

scholarly journals Autophagy activity is associated with membranous sodium iodide symporter expression and clinical response to radioiodine therapy in non-medullary thyroid cancer

Autophagy ◽  
2016 ◽  
Vol 12 (7) ◽  
pp. 1195-1205 ◽  
Author(s):  
Theo S. Plantinga ◽  
Marika H. Tesselaar ◽  
Hans Morreau ◽  
Eleonora P. M. Corssmit ◽  
Brigith K. Willemsen ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Clinical Response ◽  
Sodium Iodide ◽  
Medullary Thyroid Cancer ◽  
Radioiodine Therapy ◽  
Sodium Iodide Symporter ◽  
Medullary Thyroid ◽  
Autophagy Activity

Indirect assessment of the maximum empirical activity (250 mCi) with respect to dosimetry concepts in radioiodine therapy of metastatic differentiated thyroid cancer

2018 ◽  
Vol 39 (11) ◽  
pp. 969-975 ◽  
Author(s):  
Mohammad Abuqbeitah ◽  
Mustafa Demir ◽  
Levent Kabasakal ◽  
İffet Çavdar ◽  
Lebriz Uslu-Beşli ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Radioiodine Therapy ◽  
Indirect Assessment

scholarly journals Evaluation of Serum Tumor Markers Variation, Following The Radioactive Iodine Therapy in Patients with Differentiated Thyroid Cancer

2020 ◽  
Vol 1 (1) ◽  
Author(s):  
Sorush Niknamian
Keyword(s):  
Thyroid Cancer ◽  
Tumor Markers ◽  
Repeated Measures ◽  
Radioactive Iodine ◽  
Radioiodine Therapy ◽  
Serum Tumor Markers ◽  
Third Stage ◽  
Serological Studies ◽  
The One ◽  
Radioactive Iodine 131

Introduction: Radioactive iodine is the effective therapy in thyroid cancer. The aim of this study is to evaluate the serum tumor markers in patients under the therapy with radioactive iodine 131. Material and Methods: 45 cases of female patients aged 16-60 years with thyroid cancer surgery referred to the nuclear medicine department of Nemazi hospital for (iodine treatment after surgery) were selected. The selection was on the basis of interviewing and information of patients is consent forms. Only patients with thyroid cancer and referred for the first time without any other diseases were chosen for this study. The selected patients were prescribed a dose of 150 m Ci of I-131. From each patient, 4 mL of chelated serum for serological studies on tumor markers and 2 mL of oxalated serum for spectrophotometry studies on cell death were used in three stages. The first stage before the iodine therapy, the second stage, after 48 hours, and the third stage, 30 days after radioiodine therapy were studied and the results were evaluated by the one-way repeated measures ANOVA test. Results: According to the results of dependent paired T-Test, AFP, in the periods before, 48 hours and 1 month after radioiodine therapy, respectively were 3.46 ± 1.21 and 3.74 ± 1.37 and 3.76 ± 1.25 (p <0.0005). About CA 19-9 in the periods before, 48 hours and one month after radioiodine therapy, the results were 9.30 ± 6.32, 9.95 ± 6.92 (p = 0.040) and 11.26 ± 7.49 (p <0.0005) respectively. About CEA, the results were 1.60 ± 0.60, 1.47 ± 0.55 and 2.23 ± 0.69 (p <0.0005), respectively. In the case of tumor marker CA 15-3 results were 15.53 ± 6.48 and 1.60 ± 0.60 and 15.68 ± 6.52 (p = 0.014), respectively and in the case of ALP, results were 124.22 ± 5 and 122.2 ± 6 and 116.7 ± 7 (p <0.0005), respectively. Conclusion: According to the same studies and the acquired results, it can be concluded that the tumor markers CEA and CA19-9 are more acceptable and sustainable for monitoring the malignancy and progressive disease in patients with thyroid cancer. The decreasing ALP is normal and transient. The increase of AFP and CA15-3 is not even statistically reliable. It is recommended that the period of iodine therapy and falsely elevated tumor markers can be informed to the doctor, during the gastrointestinal studies in patients with thyroid cancer, in order to prevent wrong decisions on the treatment process.

Sign in / Sign up

Export Citation Format

Share Document